Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-25-050230
Filing Date
2025-11-06
Accepted
2025-11-06 16:30:32
Documents
72
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q allo-20250930.htm   iXBRL 10-Q 1552814
2 EX-31.1 allo-20250930xex311.htm EX-31.1 9636
3 EX-31.2 allo-20250930xex312.htm EX-31.2 9586
4 EX-32.1 allo-20250930xex321.htm EX-32.1 6902
  Complete submission text file 0001628280-25-050230.txt   7489659

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT allo-20250930.xsd EX-101.SCH 55358
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT allo-20250930_cal.xml EX-101.CAL 59424
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT allo-20250930_def.xml EX-101.DEF 351670
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT allo-20250930_lab.xml EX-101.LAB 689539
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT allo-20250930_pre.xml EX-101.PRE 509247
74 EXTRACTED XBRL INSTANCE DOCUMENT allo-20250930_htm.xml XML 871653
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

EIN.: 823562771 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38693 | Film No.: 251458940
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)